SLCO1B3: A Prognostic Marker and Immune Modulator in Oral Squamous Cell Carcinoma

Jianing Hao

doi:10.54097/cj5ffj72

Authors

Jianing Hao

DOI:

https://doi.org/10.54097/cj5ffj72

Keywords:

SLCO1B3, Oral Squamous Cell Carcinoma, A Prognostic Marker and Immune Modulator

Abstract

While clinical management of oral squamous cell carcinoma (OSCC) has seen substantial progress, its incidence and mortality rates have shown minimal improvement over the past three decades. Recent studies highlight the therapeutic potential of solute carrier organic anion transporter family member 1B3 (SLCO1B3) in head and neck squamous cell carcinoma, yet its precise mechanistic role in OSCC remains elusive. Through pan-cancer expression profiling, we identified marked heterogeneity in SLCO1B3 expression across tumor types, with marked upregulation specifically observed in OSCC tissues. Systematic analysis of clinical datasets revealed a significant inverse correlation between SLCO1B3 expression levels and critical prognostic indicators, including overall patient survival. Functional enrichment analysis further demonstrated SLCO1B3's robust association with immune infiltration signatures, suggesting its involvement in shaping the tumor immune microenvironment. By integrating ESTIMATE microenvironment scoring and single-sample gene set enrichment analysis (ssGSEA), we uncovered SLCO1B3-mediated suppression of B-cell populations—particularly naive B cells—revealing a novel mechanism of immune evasion. These findings not only establish SLCO1B3 as a prognostic biomarker for OSCC but also provide mechanistic insights for developing immune microenvironment-targeted therapies.

Downloads

Download data is not yet available.

References

[1] Tan, Yunhan., Tan, Yunhan., Wang, Zhihan., Xu, Mengtong., & Li, Bowen.. (2023). Oral squamous cell carcinomas: state of the field and emerging directions. International journal of oral science.Li, Hongjiao., Zhang, Yao., Xu, Mengmeng., & Yang, Deqin.. (2022). Current trends of targeted therapy for oral squamous cell carcinoma. Journal of cancer research and clinical oncology.

[2] Bugshan, Amr., & Farooq, Imran.. (2020). Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Research, 9, 229.Eckert, Alex&er W., Wickenhauser, Claudia., Salins, Paul C., Kappler, Matthias., & Bukur, Juergen.. (2016). Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. Journal of translational medicine, 14, 85.

[3] Smyth, Elizabeth C., Lagergren, Jesper., Lagergren, Jesper., Fitzgerald, Rebecca C., & Lordick, Florian.. (2017). Oesophageal cancer. Nature reviews. Disease primers, 3, 17048.

[4] Pignatelli, Pamela., Romei, Federica Maria., Bondi, Danilo., Giuliani, Michele., & Piattelli, Adriano.. (2022). Microbiota and Oral Cancer as A Complex and Dynamic Microenvironment: A Narrative Review from Etiology to Prognosis. International journal of molecular sciences.

[5] Sun, Ruipu., Sun, Ruipu., Ying, Ying., Tang, Zhimin., & Liu, Ting. (2020). The Emerging Role of the SLCO1B3 Protein in Cancer Resistance. Protein and peptide letters, 27(1), 17-29.

[6] Wu, Ting., & Dai, Yun. (2016). Tumor microenvironment and therapeutic response. Cancer letters, 387, 61-68.

[7] Xiao, Yi., & Yu, Dihua.. (2020). Tumor microenvironment as a therapeutic target in cancer. Pharmacology & therapeutics, 221.

[8] Vitale, Ilio., Manic, Gwenola., Coussens, Lisa M., Kroemer, Guido., & Galluzzi, Lorenzo.. (2019). Macrophages and Metabolism in the Tumor Microenvironment. Cell metabolism, 30(1).

[9] Chen, Degao., Zhang, Xiaomei., Li, Zhongjun., Zhu, Bo., & Zhu, Bo.. (2021). Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics, 11(3), 1016-1030.

[10] Pitt, J M., Marabelle, A., Eggermont, A., Soria, J-C., & Kroemer, G.. (2016). Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 27(8), 1482-92.

[11] Lee, Yeuan Ting., Tan, Yi Jer., & Oon, Chern Ein.. (2018). Molecular targeted therapy: Treating cancer with specificity. European journal of pharmacology, 834, 188-196.

[12] Johnson, Daniel E., Burtness, Barbara., Leemans, C René., Lui, Vivian Wai Yan., & Bauman, Julie E.. (2020). Head and neck squamous cell carcinoma. Nature reviews. Disease primers, 6(1), 92.

[13] Zhang Wenwen, Liu Keke, Liu Luyao, Cao Juan, Li Bo, Dong Chunling. The Role of tumor-associated fibroblasts in Oral Squamous cell carcinoma and Research Progress of Targeted Therapy [J]. China Medical Review,2019,16(14):29-32.

[14] Liu, Lian., Chen, Jili., Cai, Xinjia., Yao, Zhigang., & Huang, Junhui.. (2019). Progress in targeted therapeutic drugs for oral squamous cell carcinoma. Surgical oncology, 31, 90-97.

[15] Barbier, Roberto H., McCrea, Edel M., Lee, Kristi Y., Strope, Jonathan D., & Risdon, Emily N.. (2021). Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Scientific reports, 11(1).

[16] Ji Zhibo, Chen Ruiguo, Yang Hao, et al. Oral squamous cell carcinoma of the present situation and research progress of chemotherapy drugs [J]. Journal of anhui medical university, 2024,59 (4) : 736-741. The DOI: 10.19405 / j.carol carroll nki issn1000-1492.2024.04.028.

[17] Sun, Ruipu., Sun, Ruipu., Ying, Ying., Tang, Zhimin., & Liu, Ting.. (2020). The Emerging Role of the SLCO1B3 Protein in Cancer Resistance. Protein and peptide letters, 27(1), 17-29.

[18] Lv, Bingzhe., Lv, Bingzhe., Wang, Yunpeng., Wang, Yunpeng., & Ma, Dongjiang.. (2022). Immunotherapy: Reshape the Tumor Immune Microenvironment. Frontiers in immunology.

[19] Rezalotfi, Alaleh., Rezalotfi, Alaleh., Ahmadian, Elmira., Aazami, Hossein., & Aazami, Hossein.. (2019). Gastric Cancer Stem Cells Effect on Th17/Treg Balance; A Bench to Beside Perspective. Frontiers in oncology, 9.

[20] Ding, Yuntao., Wang, Huizhi., Cao, Wenyu., Cao, Tianyu., & Jiang, Han.. (2023). TTC22 as a potential prognostic marker and therapeutic target in pancreatic cancer: Insights into immune infiltration and epithelial‑mesenchymal transition. Oncology letters.

[21] Eibel, Hermann., Kraus, Helene., Sic, Heiko., Kienzler, Anne-Kathrin., & Rizzi, Marta. (2014). B cell biology: an overview. Current allergy and asthma reports, 14(5).

[22] Wang Y, Wang H, Shi T, Song X, Zhang X, Zhang Y, Wang X, Che K, Luo Y, Yu L, Liu B, Wei J. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. EMBO Mol Med. 2024 Sep;16(9):2170-2187. doi: 10.1038/s44321-024-00120-3. Epub 2024 Aug 20. PMID: 3916 4472; PMCID: PMC11393071.

[23] Ding Y, Wang H, Cao W, Cao T, Jiang H, Yu Z, Zhou Y, Xu M. TTC22 as a potential prognostic marker and therapeutic target in pancreatic cancer: Insights into immune infiltration and epithelial‑mesenchymal transition. Oncol Lett. 2023 Nov 10;27(1):11. doi: 10.3892/ol.2023.14143. PMID: 38034483; PMCID: PMC10688474.

[24] Ruffin, Ayana T., Ruffin, Ayana T., Ruffin, Ayana T., Ruffin, Ayana T., & Cillo, Anthony R.. (2021). B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nature communications, 12(1).